European Commission publishes update on CGD gene therapy

CORDIS, the Community Research and Development Information Service of the European Community has recently posted information on its website to bring the CGD community up to date on advances in the EU funded project on gene therapy for CGD.

This 8 million euro project called NET4CGD focuses on the clinical development of a new orphan drug of gene therapy that can rapidly become a new treatment option for people with the X-linked form of CGD.

The project taps into gene therapy expertise across Europe and uses state-of-the-art technology and has constructed an advanced lentiviral vector that carries a healthy version of the NADPH oxidase gene. The goal is to ensure the long-term engraftment of gene-modified cells in patients. Preliminary data indicate that gene corrected patient cells display restored biochemical activity and neutrophil oxidative function at therapeutic levels. The project is currently recruiting patients to take part in this clinical trial.

You can find out more by clicking on the links below: